Nutra Pharma is announcing their newest marketing plans for their over-the-counter pain relievers will utilize influencers, celebrities and athletes on social media platforms
Plantation, Florida, May 24, 2021 — McapMediaWire — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for expanding the marketing of their over-the-counter pain relievers and anti-inflammatory products by working with influencers on several social media platforms. These will include celebrities as well as professional and Olympic athletes that have benefitted from Nutra Pharma’s products.
“We have life-changing products that need much wider attention,” commented Nina Goldstein, Marketing Manager of Nutra Pharma. “While we’ve seen some real growth in retail and on-line sales of our products over the past year, we are still struggling to get brand recognition and substantial acceptance of these exceptional products,” she continued. “By working with social media influencers that are already using these products, we can reach an incredibly large audience of new potential customers. As these sales grow, it will go hand in hand with our rollout into broader retail sales across the United States and internationally,” she concluded.
Nyloxin® is a safe, non-narcotic, and non-addictive Homeopathic pain reliever for the relief of pain without impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies. Nyloxin is available as an oral spray for systemic pain and as a topical gel for targeted pain management.
Pet Pain-Away™ is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in cats and dogs. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
The company now markets Nyloxin on www.Nyloxin.com as well as their Amazon marketplace at www.Amazon.com/nyloxin. Pet Pain-Away is being marketed through www.PetPainAway.com. Equine Pain-Away is being marketed through www.EquinePainAway.com, while Luxury Feet is being marketed through www.LuxuryFeet.com.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away™, Pet Pain-Away™ and Luxury Feet™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The influencer campaign for the Company’s products should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|Nutra Pharma Corp.